



	Questions : Lok Sabha




























Screen Reader Access
Skip to Main Content
Skip to Navigation



Text Size

                                A

                                A
A















हिन्दी मे








Parliament of India Lok Sabha House of the
                        People






* Special Characters not allowed












India Time 


Your Time 


                        Tuesday,
                        12 April 2022









HomeMembersSitting MembersMembers Home PageMembers' PortalContact DetailsMembers SearchStatistical AnalysisAttendance of MembersHandbook Members Since 1952Digitized Who's WhoOthers BusinessProvisional CalendarList of BusinessPapers to be LaidList of Private Members' BusinessBulletin-IDigitized Lok Sabha Bulletin Part IBulletin-IIStatement of WorkSpecial Mentions (ZERO HOUR)Resume of WorkDigitized Resume of Work done by Lok Sabha QuestionsHomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions DebatesIntroductionSynopsisUncorrected DebateText of DebateDigitized DebatesConstituent Assembly DebatesWit And HumourDebate SearchHindi FontsDisclaimer Papers LaidPapers Laid on the Table of the House LegislationIntroduction(How Bill Becomes Act)Bills IntroducedBills PassedBills PendingBills AssentedBills LapsedBills WithdrawnBills NegativedBills Search Disclaimer CommitteesIntroductionChairpersonSummary of WorkCommittee Meetings ScheduleBills Referred to CommitteesReports PresentedDigitized ReportsPress ReleaseMembership SearchToday's Committee MeetingsCommittee Subject SelectedDepartment Related-RS Govt. AssurancesSANSAD TVIntranet





HomeQuestion ListStatus of notices of questionQuestions CalendarGrouping of Ministries - AlphabeticalOfficers in Min./Dept. Dealing with Parliamentary WorkQuestion SearchSupplementary Questions











Download as PDF




Print












PDF/WORD(Hindi)


PDF/WORD




                                    GOVERNMENT OF INDIA
                                





                                    MINISTRY OF
                                    HEALTH AND FAMILY WELFARE






                                    LOK SABHA
                                





UNSTARRED 


                                    QUESTION NO:
                                

4910






                                    ANSWERED ON: 
                                

01.04.2022






Adverse Reaction of Anti-diabetes Medicine




P. Velusamy














                        Will the Minister of





HEALTH AND FAMILY WELFARE


                        be pleased to state:-















                                                    (a) whether the Government has taken note of adverse drug reactions associated with the use of a new class of anti-diabetes medicines, SGLT-2 inhibitors in the country, if so, the details thereof;(b) whether the Government has received adverse reports of these medicines from States/UTs particularly from the State of Tamil Nadu, if so, the details thereof;(c) whether the Drug Controller of India has given permission to market this medicine in the country, if so, the details thereof; and(d) the steps taken by the Government to create awareness among millions of diabetic patients in the country against the usage of SGLT-2?






ANSWER




                                                        THE MINISTER OF STATE IN THE MINISTRY OF HEALTH ANDFAMILY WELFARE(DR. BHARATI PRAVIN PAWAR)(a):	Central Drugs Standard Control Organization (CDSCO) was notified about a Health Canada communication to all Sodium-Glucose Co-transporter-2 (SGLT2) inhibitor Marketing Authorization Holders regarding a Summary Safety Review (SSR) on the potential risk of pancreas inflammation (acute and chronic).United States Food & Drug Administration (USFDA) in its Drug Safety Communications (DSC) stated that cases of rare but serious infection of the genitals and area around the genitals have been reported with use of SGLT2 inhibitors. This serious rare infection, called necrotizing fasciitis of the perineum, is also referred to as Fournier’s gangrene. USFDA has revised the labels of SGLT 2 inhibitors to include new warnings about the risk to patients.The issue was examined in consultation with Subject Expert Committee (SEC) of CDSCO and information available under the Pharmacovigilance Programme of India (PvPI) has also been obtained.Accordingly, CDSCO has requested all State Drug Controllers to direct the manufacturers of SGLT2 inhibitor class drugs named Canagliflozin, Dapagliflozin, Empagliflozin, under their jurisdiction to include the following warning in the package insert and promotional literature of these drugs:“Warning - Cases of a rare but serious infection of the genitals and area around the genitals have been reported with this class of type 2 diabetes medicines i.e., Sodium-Glucose Cotransporter-2 (SGLT2) inhibitors. This serious rare infection, called necrotizing fasciitis of the perineum, is also referred to as Fournier’s gangrene.”(b):	The details of adverse effects (no. of adverse drug reactions reported) in respect of SGLT-2 inhibitors reported under the PvPI from Tamil Nadu are as below:Euglycaemic diabetic ketoacidosis (3), Urinary tract infection (3), Burning micturition (2), Dysuria (2), Serum creatinine increased (2), Genital inflammation (1), Balanitis (1), Genital redness (1), Chest heaviness (1), Cough (1), Cystitis (1), BUN increased (1), Hemoptysis (1), Hypotension (1), Leukorrhoea (1), Numbness of upper arm (1), Pyelonephritis (1), SGPT increased (1), Thirst excessive (1), Vaginal candidiasis (1), Urination frequency (1), Weight increase (1).(c) & (d): CDSCO has given permission to import/market formulations of following SGLT-2 inhibitors: Canagliflozin, Dapagliflozin & Empagliflozin including Fixed Dose Combinations (FDC) like Dapagliflozin + Metformin HCL, Empagliflozin +Linagliptin, Empagliflozin + Metformin HCL, Canagliflozin + Metformin HCL , Dapagliflozin + Metformin, Remogliflozin Etabonate + Metformin Hydrochloride,  Saxagliptin + Dapagliflozin , Remogliflozin Etabonate + Vildagliptin, Remogliflozin Etabonate + Teneligliptin Hydrobromide Hydrate, Remogliflozin Etabonate + Vildagliptin + Metformin Hydrochloride. Further, all the States were requested to direct the manufactures of SGLT 2 inhibitor class drugs to include warning in the package insert and promotional literature of these drugs.******
























HomeArchiveIndex to Select Questions (1984-1999)Ballot ListStatistical Statements Relating to QuestionsUploading of Questions - Status QueryProcedure for Sending Text of Questions & AnswersDemarcation of responsibilities in Govt. of IndiaBrochure on Statutory Corporations, Companies and Other Bodies in Which the Government of India have financial or controlling interestHighlights pertaining to questions of 17th Lok Sabha






Contact Us 
Disclaimer











        Developed and Hosted by National Informatics Centre (NIC)

Content on this website is published,
            managed & maintained by Software Unit, Computer (HW & SW) Management. Branch,
            Lok Sabha Secretariat





HomeMembersBusinessQuestionsDebatesPapers Laid


LegislationCommitteesSANSAD TVIntranetSecretariatPRIDE


RecruitmentSC/ST ReservationConferenceParliament Library


About ParliamentPhoto GalleryRelated LinksRTITendersFAQ


SpeakerDy. SpeakerLeader of the HousePanel of ChairpersonsContact UsFeedback


Council of MinistersPublications of MinistriesParliamentry ProceduresJournal of Parliamentary Information
Visitor's Counter:113264803







Copyright
Privacy Policy
Disclaimer
Terms &
                Conditions

                Accessibility Statement
Accessibility
                Options
Feedback
Site Map







